New combo tackles resistant prostate cancer
NCT ID NCT05177042
First seen Apr 30, 2026 · Last updated Apr 30, 2026
Summary
This early-phase trial tested a new drug (ARV-110) combined with the standard drug abiraterone in 45 men whose metastatic prostate cancer was worsening despite abiraterone alone. The main goals were to check safety and find the best dose. The study is complete, but results are not yet public.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Santa Monica, California, 91361, United States
-
Clinical Trial Site
New Haven, Connecticut, 06519, United States
-
Clinical Trial Site
Fort Myers, Florida, 33916, United States
-
Clinical Trial Site
Boston, Massachusetts, 02114, United States
-
Clinical Trial Site
Columbus, Ohio, 43210, United States
-
Clinical Trial Site
Portland, Oregon, 97239, United States
-
Clinical Trial Site
Myrtle Beach, South Carolina, 29572, United States
-
Clinical Trial Site
Nashville, Tennessee, 37203, United States
-
Clinical Trial Site
Charlottesville, Virginia, 22903, United States
-
Clinical Trial Site
Vancouver, British Columbia, Canada
-
Clinical Trial Site
Toronto, Ontario, Canada
-
Clinical Trial Site
Montreal, Quebec, Canada
-
Clinical Trial Site
Caen, France
-
Clinical Trial Site
Paris, France
-
Clinical Trial Site
Villejuif, France
-
Clinical Trial Site
London, England, United Kingdom
-
Clinical Trial Site
Cardiff, Wales, United Kingdom
-
Clinical Trial Site
Preston, PR2 9HT, United Kingdom
Conditions
Explore the condition pages connected to this study.